Astellas Pharma (JP:4503) has released an update.
Astellas Pharma Inc.’s zolbetuximab, a novel treatment for advanced gastric and gastroesophageal junction cancer, has received a positive opinion from the CHMP, recommending its approval in the EU. If sanctioned, it will be the first CLDN18.2-targeted therapy in the EU, responding to a high demand for new treatments in a region where gastric cancer is the sixth leading cause of cancer death. The positive recommendation is backed by results from the SPOTLIGHT and GLOW Phase 3 trials.
For further insights into JP:4503 stock, check out TipRanks’ Stock Analysis page.
